Axsome Therapeutics, Inc.: RBC cuts target price to $295 from $297
AXSM•RBC cut its target price for Axsome Therapeutics to $295 from $297.
Related News
Gain Therapeutics to attend Maxim Growth Summit
GANX•
Veeva hosts R&D and Quality Summit spotlighting AI innovations in biopharma operations
VEEV•
Corn drifts as USDA data awaited for harvest clues
DBA•
Latham Group Inc: William Blair cuts rating to market perform
SWIM•
Limbach Holdings Inc: Stifel cuts target price to $75 from $86
LMB•